Waters Corporation is expected to report Q1 2026 consensus revenue of $1.20 billion and EPS of $2.31, with the stock currently trading at $307.12—a significant discount to the average analyst price target of $387.53.
Investors are primarily focused on the operational integration of the $17.5 billion BD Biosciences and Diagnostic Solutions acquisition, which is the primary driver behind the massive year-over-year revenue leap.
While Waters delivered industry-leading results in 2025 with high single-digit organic growth, the stock suffered a 14% decline in February following softer-than-expected near-term profit guidance.
Market participants are now looking for evidence that the instrument replacement cycle and high-margin recurring chemistry sales can offset integration-related margin pressures and sluggish demand in clinical segments.